FDA Issues No-Questions Letter for Sunflower Lecithin GRAS Notice

What FDA Posted

FDA's GRAS notice inventory lists GRN 001267 for sunflower lecithin with a February 17, 2026 status stating that the agency has no questions at this time regarding the notifier's conclusion that the ingredient is generally recognized as safe under the intended conditions of use.

The posting gives buyers a current public reference for a sunflower-derived lecithin submission rather than relying only on older market practice or private supplier claims.

Why It Matters

Sunflower-origin materials matter to brands that want a non-soy positioning or need an additional phospholipid source in food and supplement systems.

A no-questions outcome does not remove the need for application-specific due diligence, but it does signal that identity, manufacturing, and use-level arguments were organized well enough to pass FDA's initial review.

Buyer Takeaway

Procurement teams comparing lecithin and phospholipid sources should ask suppliers for the same core file elements visible in GRAS work: source description, process narrative, compositional specifications, and intended-use framing.

That document discipline becomes more important when sunflower-derived inputs are being qualified as a substitute or second source in existing formulations.

Fontes

• GRAS Notices
• GRAS Notice No. GRN 001267